Versant Vantage I, L.p. - Net Worth and Insider Trading

Versant Vantage I, L.p. Net Worth

The estimated net worth of Versant Vantage I, L.p. is at least $13 Million dollars as of 2024-09-20. Versant Vantage I, L.p. is the 10% Owner of Repare Therapeutics Inc and owns about 3,544,862 shares of Repare Therapeutics Inc (RPTX) stock worth over $12 Million. Versant Vantage I, L.p. is also the 10% Owner of Aprea Therapeutics Inc and owns about 142,633 shares of Aprea Therapeutics Inc (APRE) stock worth over $416,488. Details can be seen in Versant Vantage I, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Versant Vantage I, L.p. has not made any transactions after 2022-06-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Versant Vantage I, L.p.

To

Versant Vantage I, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Versant Vantage I, L.p. owns 9 companies in total, including Aligos Therapeutics Inc (ALGS) , Black Diamond Therapeutics Inc (BDTX) , and Pandion Therapeutics Inc (PAND) among others .

Click here to see the complete history of Versant Vantage I, L.p.’s form 4 insider trades.

Insider Ownership Summary of Versant Vantage I, L.p.

Ticker Comapny Transaction Date Type of Owner
ALGS Aligos Therapeutics Inc 2020-10-15 10 percent owner
BDTX Black Diamond Therapeutics Inc 2020-01-29 10 percent owner
PAND Pandion Therapeutics Inc 2020-07-21 10 percent owner
LIMIT LIMIT 2022-06-03 10 percent owner
LIMIT LIMIT 2020-05-18 10 percent owner
LIMIT LIMIT 2020-02-27 10 percent owner
LIMIT LIMIT 2019-10-30 10 percent owner
LIMIT LIMIT 2021-06-23 10 percent owner
LIMIT LIMIT 2023-09-14 10 percent owner

Versant Vantage I, L.p. Latest Holdings Summary

Versant Vantage I, L.p. currently owns a total of 2 stocks. Among these stocks, Versant Vantage I, L.p. owns 3,544,862 shares of Repare Therapeutics Inc (RPTX) as of June 3, 2022, with a value of $12 Million and a weighting of 96.75%. Versant Vantage I, L.p. also owns 142,633 shares of Aprea Therapeutics Inc (APRE) as of October 7, 2019, with a value of $416,488 and a weighting of 3.25%.

Latest Holdings of Versant Vantage I, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RPTX Repare Therapeutics Inc 2022-06-03 3,544,862 3.50 12,407,017
APRE Aprea Therapeutics Inc 2019-10-07 142,633 2.92 416,488

Holding Weightings of Versant Vantage I, L.p.


Versant Vantage I, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Versant Vantage I, L.p. has made a total of 2 transactions in Repare Therapeutics Inc (RPTX) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Repare Therapeutics Inc is the sale of 750,000 shares on June 3, 2022, which brought Versant Vantage I, L.p. around $9 Million.

According to the SEC Form 4 filings, Versant Vantage I, L.p. has made a total of 1 transactions in Aprea Therapeutics Inc (APRE) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Aprea Therapeutics Inc is the acquisition of 16,667 shares on October 7, 2019, which cost Versant Vantage I, L.p. around $5 Million.

Insider Trading History of Versant Vantage I, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Versant Vantage I, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Versant Vantage I, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Versant Vantage I, L.p. is 57.13%. GuruFocus also compares Versant Vantage I, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Versant Vantage I, L.p. within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Versant Vantage I, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Versant Vantage I, L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -6.37 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -10.52 LIMIT LIMIT LIMIT LIMIT LIMIT

Versant Vantage I, L.p. Ownership Network

Ownership Network List of Versant Vantage I, L.p.

No Data

Ownership Network Relation of Versant Vantage I, L.p.

Insider Network Chart

Versant Vantage I, L.p. Owned Company Details

What does Aligos Therapeutics Inc do?

Who are the key executives at Aligos Therapeutics Inc?

Versant Vantage I, L.p. is the 10 percent owner of Aligos Therapeutics Inc. Other key executives at Aligos Therapeutics Inc include 10 percent owner Roche Holding Ltd , 10 percent owner Roche Finance Ltd , and Chief Medical Officer Matthew W. Mcclure .

Aligos Therapeutics Inc (ALGS) Insider Trades Summary

Over the past 18 months, Versant Vantage I, L.p. made no insider transaction in Aligos Therapeutics Inc (ALGS). Other recent insider transactions involving Aligos Therapeutics Inc (ALGS) include a net purchase of 7,933,601 shares made by Carole Nuechterlein ,

In summary, during the past 3 months, insiders sold 0 shares of Aligos Therapeutics Inc (ALGS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aligos Therapeutics Inc (ALGS) were sold and 317,344 shares were bought by its insiders, resulting in a net purchase of 317,344 shares.

Aligos Therapeutics Inc (ALGS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aligos Therapeutics Inc Insider Transactions

No Available Data

Versant Vantage I, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Versant Vantage I, L.p.. You might contact Versant Vantage I, L.p. via mailing address: One Sansome, Suite 1650, San Francisco Ca 94104.

Discussions on Versant Vantage I, L.p.

No discussions yet.